Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on the signature page)
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Fred Aslan, M.D. and Thad Huston and each of them, as his or her true and lawful attorneys-in-fact and agents, and each of them, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Fred Aslan, M.D. | President and Chief Executive Officer | March 10, 2026 |
| Fred Aslan, M.D. | (Principal Executive Officer) | |
| /s/ Thad Huston | Chief Financial Officer (Principal Financial and Accounting Officer) | March 10, 2026 |
| Thad Huston | ||
| /s/ Brian Daniels, M.D. | Director and Board Chair | March 10, 2026 |
| Brian Daniels, M.D. | ||
| /s/ Elizabeth Hougen | Director | March 10, 2026 |
| Elizabeth Hougen | ||
| /s/ Diego Miralles, M.D. | Director | March 10, 2026 |
| Diego Miralles, M.D. | ||
| /s/ Alison Moore | Director | March 10, 2026 |
| Alison Moore | ||
| /s/ Laura Stoppel, Ph.D. | Director | March 10, 2026 |
| Laura Stoppel, Ph.D. | ||
| /s/ Elaine Sorg | Director | March 10, 2026 |
| Elaine Sorg | ||
| /s/ Daniel Baker, M.D. | Director | March 10, 2026 |
| Daniel Baker, M.D. | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (KPMG LLP, San Diego, California; PCAOB ID: 185) | F-2 |
|---|---|
| Balance Sheets | F-3 |
| Statements of Operations and Comprehensive Loss | F-4 |
| Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) | F-5 |
| Statements of Cash Flows | F-6 |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.